title: Visceral leishmaniasis infection in a fingolimod-treated multiple sclerosis patient.
authors.affiliation: 1st Department of Neurology, Aeginition Hospital, School of Medicine, Kapodistrian University of Athens, Athens, Greece kmwartem@yahoo.com.
authors.forename: A K
authors.initials: AK
authors.lastname: Artemiadis
authors.affiliation: Department of Neurology, NIMTS Hospital, Athens, Greece.
authors.forename: G
authors.initials: G
authors.lastname: Nikolaou
authors.affiliation: Department of Hematology, NIMTS Hospital, Athens, Greece.
authors.forename: D
authors.initials: D
authors.lastname: Kolokythopoulos
authors.affiliation: Hellenic Centre for Diseases Control and Prevention, Ministry of Health, Athens, Greece.
authors.forename: N
authors.initials: N
authors.lastname: Tegos
authors.affiliation: Department of Neurology, NIMTS Hospital, Athens, Greece.
authors.forename: A
authors.initials: A
authors.lastname: Terentiou
authors.affiliation: 1st Department of Neurology, Aeginition Hospital, School of Medicine, Kapodistrian University of Athens, Athens, Greece.
authors.forename: N
authors.initials: N
authors.lastname: Triantafyllou
authors.affiliation: Department of Neurology, NIMTS Hospital, Athens, Greece.
authors.forename: I
authors.initials: I
authors.lastname: Papanastasiou
mesh_terms: D000328:Adult; D005260:Female; D000068876:Fingolimod Hydrochloride / Q000009:adverse effects*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D007898:Leishmaniasis, Visceral / Q000175:diagnosis* / Q000276:immunology; D009103:Multiple Sclerosis / Q000188:drug therapy*
chemical_list: D007166:Immunosuppressive Agents; D000068876:Fingolimod Hydrochloride
keywords: Visceral; fingolimod; infection; leishmaniasis; multiple sclerosis; side-effect